MARKET

CYTH

CYTH

Cyclo Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.020
+0.050
+2.54%
Closed 16:00 07/01 EDT
OPEN
1.990
PREV CLOSE
1.970
HIGH
2.090
LOW
1.930
VOLUME
8.11K
TURNOVER
5.78K
52 WEEK HIGH
10.40
52 WEEK LOW
1.880
MARKET CAP
17.00M
P/E (TTM)
-1.0787
1D
5D
1M
3M
1Y
5Y
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla., June 21, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and famili...
Business Wire · 06/21 12:05
Top Premarket Gainers
MT Newswires · 05/25 08:08
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
GAINESVILLE, Fla., May 18, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and fa...
Business Wire · 05/18 12:00
Cyclo Therapeutics GAAP EPS of -$0.33 beats by $0.14, revenue of $0.19M misses by $0.36M
Cyclo Therapeutics press release (NASDAQ:CYTH): Q1 GAAP EPS of -$0.33 beats by $0.14. Revenue of $0.19M (-47.2% Y/Y) misses by $0.36M.
Seekingalpha · 05/12 20:56
BRIEF-Cyclo Therapeutics Reports First Quarter 2022 Financial Results
reuters.com · 05/12 20:26
-- Earnings Flash (CYTH) CYCLO THERAPEUTICS Reports Q1 Loss $-0.33
MT Newswires · 05/12 16:27
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
GAINESVILLE, Fla., May 09, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and fa...
Business Wire · 05/09 12:05
4 Penny Stocks Insiders Are Buying
US crude oil futures traded sharply lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...
Benzinga · 03/31 10:16
More
No Data
Learn about the latest financial forecast of CYTH. Analyze the recent business situations of Cyclo Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CYTH stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
High10.00
Average10.00
Low10.00
Current 2.020
EPS
Actual
Estimate
-0.61-0.46-0.30-0.15
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 13
Institutional Holdings: 434.11K
% Owned: 5.16%
Shares Outstanding: 8.42M
TypeInstitutionsShares
Increased
6
18.92K
New
1
1.23K
Decreased
2
10.92K
Sold Out
3
33.35K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.68%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Chief Executive Officer/Director
Nathan Fine
Chief Financial Officer
Joshua Fine
Chief Operating Officer/Chief Scientific Officer/Director/IR Contact Officer
Jeffrey Tate
Executive Vice President
George Fails
Senior Vice President
Sharon Hrynkow
Lead Director/Independent Director
Markus Sieger
Director
William Shanahan
Director
C. E. Rick Strattan
Director
Randall Toig
Independent Director
F. Patrick Ostronic
No Data
No Data
About CYTH
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Webull offers kinds of Cyclo Therapeutics Inc stock information, including NASDAQ:CYTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTH stock methods without spending real money on the virtual paper trading platform.